Secukinumab, a first in class, anti-IL-17A monoclonal antibody, fully human-has demonstrated sustained and strong efficacy with a fine safety profile, in the treatment of patients with psoriatic arthritis, ankylosing spondylitis and moderate-to-severe plaque psoriasis [1–6]. Here, IL17A is linked to psoriasis vulgaris.